Latest Research
All of our doctors are actively involved in clinical studies and trials to improve the healthcare of our patients.
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology. Trends Endocrinol Metab. 2025.
SGLT-2 inhibitors and GLP-1 receptor agonists, new medications that reduce the risk of heart disease in people with and without type 2 diabetes, may have a role to play in mitigating cardiovascular risk in type 1 diabetes.
Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas. European Journal of Endocrinology 2025.
International updated guidelines on how to diagnose and manage aggressive pituitary tumours.
Pituitary Incidentaloma: a Pituitary Society international consensus guideline statement. Nature Reviews Endocrinology 2025
Pituitary tumours are frequently picked up incidentally on brain imaging. While often not causing any clinical concern they can sometimes be causing hormonal disturbance or grow over time. This guideline document details how best to investigate these and how often to image.
Impact of body weight loss on type 2 diabetes remission. Lancet Diabetes Endocrinol 2025.
Losing weight—especially >10% —can dramatically improve the chances of reversing type 2 diabetes, regardless of other clinical factors. In this study, every 1% of weight loss increased the chance of diabetes remission by about 2%.
Editorial commentary: Understanding the cardiovascular benefits of glucagon-like peptide-1 (GLP-1) receptor agonists. Trends in Cardiovascular Medicine. 2024.
Over the last two decades the therapeutic options for management of type 2 diabetes and obesity have dramatically expanded. The mandated cardiovascular safety trials have uncovered further therapeutic benefits of glucagon-like peptide-1 receptor agonist.
Cycle characterisation and clinical complications in patients with cyclic Cushing’s syndrome: insights from an international retrospective cohort study.
Cyclic Cushing’s syndrome causes cortisol levels to rise and fall unpredictably, making diagnosis difficult and often delayed, even in expert centers. Careful timing of tests and frequent saliva cortisol checks can help improve detection.
Considerations of delayed gastric emptying with peri-operative use of glucagon-like peptide-1 receptor agonists. Medical Journal of Australia. 2024.
Glucagon-like peptide-1 receptor agonists delay gastric emptying which can be an issue with anaesthetic; however, their benefits, particularly for people with type 2 diabetes, usually outweigh this risk.
Classification of type 1 diabetes: A pathogenic and treatment-based classification. Diabetes Metab Syndr. 2024.
Some people with type 1 diabetes do not have the classic autoantibodies that are usually present at diagnosis. People with antibody-negative type 1 diabetes appear to have a similar natural history to those with antibody-positive type 1 diabetes.